Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 7/20 | 0.53 |
| ▸ | PPARG | P37231 | 8/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | CCR9 | P51686 | 2/20 | 0.46 |
| ▸ | RHEB | Q15382 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4209306 | 0.89 | CCR9 (0.56) | CCR2CCR9RHEB | |
| SCHEMBL6303493 | 0.84 | CCR2 (0.62) | CCR2CCR9RHEB | |
| SCHEMBL6308312 | 0.82 | CCR9 (0.55) | CCR2PPARGTHRBCCR9 | |
| SCHEMBL4655319 | 0.81 | CCR2 (0.67) | CCR2PPARGCCR9 | |
| SCHEMBL6300706 | 0.81 | CCR9 (0.53) | CCR2PPARGCCR9RHEB | |
| SCHEMBL3963296 | 0.77 | CCR2 (0.72) | CCR2THRBRHEB | |
| SCHEMBL701444 | 0.75 | GPR35 (0.46) | CCR2CCR9RHEB | |
| SCHEMBL4657609 | 0.74 | CCR2 (0.71) | CCR2PPARGCCR9 | |
| SCHEMBL7194615 | 0.74 | SRD5A1 (0.56) | CCR2PPARGTHRBCCR9 | |
| SCHEMBL6300893 | 0.72 | CCR2 (0.63) | CCR2PPARGCCR9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6953809-B2 | Monocyte chemoattractant protein-1 inhibitor compounds | ZENECA LIMITED (GB) | 2005-10-11 | — | — | US | disclosed |
| US-20030119830-A1 | Monocyte chemoattractant protein-1 inhibitor compounds | ZENECA LIMITED | 2003-06-26 | — | — | US | disclosed |
| US-6441004-B1 | INDOLE DERIVATIVES AS ANTIINFLAMMATORY AGENTS | ZENECA LIMITED (GB) | 2002-08-27 | — | — | US | disclosed |
| EP-1003504-A2 | INDOLE DERIVATIVES AND THEIR USE AS MCP-1 ANTAGONISTS | AstraZeneca UK Limited (GB) | 2000-05-31 | — | — | EP | disclosed |
| WO-1999007351-A2 | INDOLE DERIVATIVES AND THEIR USE AS MCP-1 ANTAGONISTS | ZENECA LIMITED (GB) | 1999-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030119830-A1 | Monocyte chemoattractant protein-1 inhibitor compounds | CCL2, CCL11, CCR1 | CCR2 4/4885PPARG 1447/4885THRB 4055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.